FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2022:... June 4, 2022 Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia June 14, 2018 Breast Cancer Warrior’s Emotional Photoshoot Features Her Husband Shaving Her Head August 21, 2019 EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... December 17, 2021 Load more HOT NEWS Loving Yourself Why Keeping Up With Your Cancer Screening Is So Important Meet Rosalie: St. Jude Children’s Research Hospital’s New Service Dog For... Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead...
